Introduction Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory infections worldwide, particularly among newborns, infants, young children, the elderly, and ...

Respiratory Syncytial Virus (RSV) is a major cause of acute respiratory tract infections (ARTIs) and can trigger outbreaks in vulnerable settings such as nursing homes, pediatric wards, and neonatal ...

Background Respiratory syncytial virus (RSV) remains the leading cause of serious viral bronchiolitis and pneumonia in infants and young children throughout the world. The burden of disease is ...

The final, formatted version of the article will be published soon. An Expression of Concern onRapid Scanning Electron Microscopy Detection and Sequencing of Severe Acute Respiratory Syndrome ...

About ENFLONSIA™ (clesrovimab-cfor) ENFLONSIA is Merck’s extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) ...

Generally, muscle strength will further decrease at the time of an acute infection. The first sign of respiratory muscle weakness may be acute respiratory insufficiency during a severe viral lower ...